Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.20
-2.19 (-26.10%)
At close: Nov 13, 2026, 4:00 PM EST
6.10
-0.10 (-1.61%)
After-hours: Nov 13, 2026, 7:55 PM EST
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
486.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 217.52M |
| Arbutus Biopharma | 181.49M |
| Zevra Therapeutics | 147.76M |
| Ginkgo Bioworks Holdings | 130.75M |
| Wave Life Sciences | 70.92M |
| Aclaris Therapeutics | 6.40M |
CADL News
- 2 days ago - Candel Therapeutics price target lowered to $11 from $15 at Freedom Broker - TheFly
- 2 days ago - Candel Therapeutics price target lowered to $18 from $23 at H.C. Wainwright - TheFly
- 2 days ago - Candel Therapeutics price target lowered to $13 from $25 at Canaccord - TheFly
- 2 days ago - Candel Therapeutics price target lowered to $15 from $18 at BofA - TheFly
- 2 days ago - Candel Therapeutics price target lowered to $19 from $22 at Stifel - TheFly
- 3 days ago - Candel Therapeutics says in ongoing dialogue with FDA on aglatimagene BLA - TheFly
- 3 days ago - Candel Therapeutics reports Q3 EPS (28c), consensus (31c) - TheFly
- 3 days ago - Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire